Adagio Medical, Inc. products

iCLAS ultra-low temperature cryoablation (ULTC) system has been developed with the vision of bringing the durability of Cox-Maze procedure1 to percutaneous transcatheter treatment of atrial arrhythmias. ULTC technology utilizes -196°C nitrogen flow to rapidly freeze myocardial tissue to form durable, contiguous, transmural lesions2. The data from multi-center European trial of ULTC showed 85% single-procedure freedom from AF at 12 months in persistent AF patients along with 1.5% rate of transient device-related complications3. In the U.S.A. iCLAS system is an investigational device, limited by Federal law to investigational use (IDE #G180623).